Botulinum toxin type A

Generic Name: Botulinum toxin type A

Brand Names: Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 93384-43-1

Unique Ingredient Identifier: 0A6JH35GMQ

Background: In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other condit...

Indication: Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.
...

Associated Conditions: Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Associated Therapies: -

Clinical Trials

Migraine Medication Effects on Urinary Symptoms

Conditions: Bladder Pain Syndrome
Migraine Disorders
Migraine
Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor
Interstitial Cystitis

Interventions: Drug: Ubrogepant
Drug: Botulinum toxin A
Drug: Rimegepant
Drug: Atogepant
Drug: Eptinezumab
Drug: Fremanezumab
Drug: Galcanezumab
Drug: Erenumab

First Posted Date: 2024-01-19

Last Posted Date: 2024-05-16

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 200

Registration Number: NCT06212661

Locations: 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy

Phase 3

Not yet recruiting

Conditions: Spasticity/Paresis
Cerebral Palsy

Interventions: Device: ESWT
Drug: Botulinum Toxin Type A
Other: Serial Casting
Behavioral: Physical Therapy
Behavioral: Occupational Therapy

First Posted Date: 2023-11-13

Last Posted Date: 2023-11-18

Lead Sponsor: Kocaeli University

Target Recruit Count: 40

Registration Number: NCT06128616

A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared with Placebo Injections in Participants Aged 18 Years and Older with Chronic Nerve Pain After Shingles or Nerve Injury

Phase 2

Recruiting

Conditions: Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Interventions: Biological: IncobotulinumtoxinA
Biological: Placebo

First Posted Date: 2023-10-19

Last Posted Date: 2024-12-20

Lead Sponsor: Merz Therapeutics GmbH

Target Recruit Count: 120

Registration Number: NCT06091020

Locations: 🇧🇬
Merz Investigational Site #3590002, Sofia, Bulgaria
🇧🇬
Merz Investigational Site #3590003, Veliko Turnovo, Bulgaria
🇧🇬
Merz Investigational Site #3590005, Sofia, Bulgaria

and more 28 locations

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Phase 3

Recruiting

Conditions: Episodic Migraine

Interventions: Other: Placebo
Biological: Botulinum toxin type A

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-02

Lead Sponsor: Ipsen

Target Recruit Count: 714

Registration Number: NCT06047457

Locations: 🇺🇸
840042, Miami, Florida, United States
🇺🇸
840057, Kingwood, West Virginia, United States
🇺🇸
840024, Birmingham, Alabama, United States

and more 79 locations

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Phase 3

Recruiting

Conditions: Chronic Migraine

Interventions: Other: Placebo
Biological: Botulinum toxin type A

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-02

Lead Sponsor: Ipsen

Target Recruit Count: 720

Registration Number: NCT06047444

Locations: 🇺🇸
840057, Kingwood, West Virginia, United States
🇺🇸
840024, Birmingham, Alabama, United States
🇺🇸
840018, Phoenix, Arizona, United States

and more 98 locations